3-methylsulfanyl-isoquinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 3-methylsulfanyl-isoquinoline
• 英文别名: 3-Methylmercapto-isochinolin；Isoquinoline, 3-methylthio-；3-methylsulfanylisoquinoline
• 化学式: C₁₀H₉NS
• 分子量: 175.254
• InChiKey: SNRLRUIFMJGALU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-羟基异喹啉 在 sodium hydroxide 、 1,2,3,4-四氢萘 、 水 、 phosphorous (V) sulfide 作用下， 生成 3-methylsulfanyl-isoquinoline
  参考文献：
  名称：

  479.杂环物质的电离常数。第三部分 吡啶，喹啉和异喹啉的巯基衍生物

  摘要：

  DOI：

  10.1039/jr9590002384

文献信息

• [EN] AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS<br/>[FR] AZASPIROCYCLES SERVANT DE MODULATEURS DE LA MONOACYLGLYCÉROL LIPASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021191390A1

  公开（公告）日：2021-09-30

  Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3, m, n, o, and p are defined herein.

  式(I)的Azaspirocycle化合物，以及其药学上可接受的盐、同位素、N-氧化物、溶剂合物和立体异构体，含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、紊乱和症状的方法，例如与疼痛、精神紊乱、神经紊乱（包括但不限于重度抑郁症、治疗抵抗性抑郁症、焦虑性抑郁症、自闭症谱系障碍、阿斯伯格综合症、双相情感障碍）、癌症和眼部疾病相关的方法：其中X、R1、R2a、R2b、R3、m、n、o和p在此处定义。
• Copper-Catalyzed Methylthiolation of Aryl Iodides and Bromides with Dimethyl Disulfide in Water
  作者：Xiang-mei Wu、Ying-yu Wang、Ming-hua Yang

  DOI：10.1055/s-0040-1707131

  日期：2020.7

  An efficient route to aryl methyl sulfides through the copper-catalyzed coupling reaction of aryl iodides or bromides with dimethyl disulfide in water is described. Electron-donating and electron-withdrawing functional groups in the substrates were tolerated, and the corresponding products were obtained in moderate to good yields.

  描述了通过芳基碘化物或溴化物与二甲基二硫化物在水中的铜催化偶联反应获得芳基甲基硫化物的有效途径。底物中的给电子和吸电子官能团是耐受的，并且以中等至良好的产率获得了相应的产物。
• MODIFIED ANTIBODIES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
  申请人：IGENICA BIOTHERAPEUTICS, INC.

  公开号：US20160130349A1

  公开（公告）日：2016-05-12

  Provided herein are modified antibodies, compounds used to make them, and intermediates in their synthesis; compositions; formulations and methods, including methods of treating diseases, disorders or conditions, for example, cancer, in humans.
• NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE
  申请人：IGENICA BIOTHERAPEUTICS, INC.

  公开号：US20160367699A1

  公开（公告）日：2016-12-22

  Provided herein are antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers
• [EN] SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE CHD1L ONCOGÈNES PRÉSENTANT UNE ACTIVITÉ PRÉCLINIQUE CONTRE LE CANCER COLORECTAL
  申请人：UNIV COLORADO REGENTS

  公开号：WO2021195279A2

  公开（公告）日：2021-09-30

  Treatment of CHD1L-driven cancers, including TCF transcription-driven cancers and EMT-driven cancers using CHD1L inhibitors. Small molecule inhibitors of CHDL1 which inhibit CHD1L ATPase and inhibit CHD1L-dependent TCF-transcription have been identified. CHD1L inhibitors prevent the TCF-complex from binding to Wnt response elements and promoter sites. More specifically, CHD1L inhibitors induce the reversion of EMT. CHD1L inhibitors are useful in the treatment of various cancers and particularly CRC and m-CRC. The CHD1L-driven cancer is among others, CRC, breast cancer, glioma, liver cancer, lung cancer or gastrointestinal (GI) cancers. CHD1L inhibitors of formulas I and XX and salts thereof as defined herein are provided as well as pharmaceutical compositions containing CHD1L inhibitors. Synergistic combinations of CHD1L inhibitors with other antineoplastic agents are also described.